RE:RE:RE:G12C/G12V KRAS mutation in PC & CRC patients respond to PelaHaving identified G12D and G12V KRAS mutations as biomarkers responsive to pelareorep in pancreatic and colorectal cancers, ONCY will be able to submit this biomarker data in their application for Accelerated Approval in both these cancers .
Single-Cell Applications of Next-Generation Sequencing
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771363/